Precipio, Inc. (PRPO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Precipio, Inc. (PRPO) Healthcare & Pipeline Overview

Precipio, Inc. operates in the healthcare sector, focusing on innovative diagnostic solutions for blood cancers, leveraging proprietary technologies to enhance testing accuracy and collaborating with academic institutions for advanced research.

What Is the Investment Thesis for PRPO?

Precipio, Inc. presents a unique investment thesis driven by its innovative diagnostic technologies and strategic collaborations. The company has a market capitalization of $41.8M and a gross margin of 44.5%, indicating operational efficiency in its product offerings. The proprietary ICE-COLD PCR technology, which enhances test sensitivity, positions Precipio favorably in a competitive market where accuracy is paramount. Furthermore, ongoing collaborations with academic institutions could lead to new product developments and research breakthroughs, potentially expanding the company's market reach. However, the company faces risks such as a negative profit margin of -1.5%, which could impact its financial stability if not addressed. Investors should monitor upcoming product launches and regulatory approvals as key growth catalysts that may influence the company's performance in the near term.

Based on FMP financials and quantitative analysis

PRPO Key Highlights

• Market capitalization of $41.8M reflects a growing interest in innovative healthcare solutions.
• Gross margin of 44.5% indicates strong operational efficiency in the diagnostic product segment.
• Negative profit margin of -1.5% highlights the need for improved cost management and revenue generation.
• Beta of 1.20 suggests higher volatility compared to the broader market, indicating potential investment risks.
• No dividend yield as the company reinvests earnings into growth and development initiatives.

Who Are PRPO's Competitors?

PRPO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRPO's Key Strengths?

• Innovative proprietary technologies that enhance diagnostic accuracy.
• Strong partnerships with academic institutions for research and development.
• Specialized focus on blood cancer diagnostics, addressing a critical healthcare need.

What Are PRPO's Weaknesses?

• Negative profit margin indicating potential financial instability.
• Limited market presence compared to larger competitors.
• Dependence on a narrow range of diagnostic products.

What Could Drive PRPO Stock Higher?

• Launch of new diagnostic products aimed at enhancing blood cancer testing accuracy.
• Collaborations with academic institutions to advance cancer research and diagnostics.
• Regulatory submissions for new diagnostic technologies to expand product offerings.

What Are the Key Risks for PRPO?

• Financial-distress signal — its Altman Z-Score of -1.80 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-6.7%) — the business is not currently generating profit on shareholder capital.
• Regulatory hurdles that may delay product approvals and market entry.
• Financial instability due to negative profit margins impacting operational sustainability.
• Increased competition from larger diagnostic companies could limit market share.

What Are the Growth Opportunities for PRPO?

• Growth opportunity 1: The global market for blood cancer diagnostics is estimated to grow at a CAGR of 7.2%, reaching $15 billion by 2027. Precipio's specialized diagnostic services and proprietary technologies, such as HemeScreen and ICE-COLD PCR, position the company to capture a significant share of this expanding market as healthcare providers increasingly seek accurate and efficient testing solutions.
• Growth opportunity 2: The increasing demand for personalized medicine is driving the need for advanced diagnostic tools. Precipio's collaboration with academic institutions specializing in cancer research can lead to the development of innovative diagnostic products tailored to specific patient needs, enhancing the company's product offerings and market appeal over the next five years.
• Growth opportunity 3: The rise of telemedicine and remote diagnostics presents an opportunity for Precipio to expand its service delivery model. By integrating its diagnostic services with telehealth platforms, the company can reach a broader patient base, particularly in underserved areas, thereby increasing its revenue potential and market penetration.
• Growth opportunity 4: The COVID-19 pandemic has heightened awareness of the importance of rapid and accurate testing. Precipio's experience in developing COVID-19 antibody tests can be leveraged to diversify its product portfolio, potentially leading to new revenue streams as the demand for testing solutions evolves in the post-pandemic landscape.
• Growth opportunity 5: Regulatory advancements and streamlined approval processes for diagnostic products can accelerate Precipio's ability to bring new technologies to market. By staying ahead of regulatory trends and maintaining compliance, the company can enhance its product development timelines and capitalize on emerging opportunities in the diagnostics sector.

What Opportunities Does PRPO Have?

• Growing demand for personalized medicine and advanced diagnostic tools.
• Expansion into telemedicine and remote diagnostic services.
• Potential for new product development through academic collaborations.

What Threats Does PRPO Face?

• Intense competition from established diagnostic companies.
• Regulatory challenges and potential delays in product approvals.
• Market volatility and economic downturns impacting healthcare spending.

What Are PRPO's Competitive Advantages?

• Proprietary technologies, such as ICE-COLD PCR, enhance testing sensitivity and accuracy.
• Strong collaborations with academic institutions provide access to cutting-edge research and development.
• Focused expertise in blood cancer diagnostics differentiates Precipio from broader diagnostic companies.
• Established reputation in the healthcare community for innovative diagnostic solutions.

What Does PRPO Do?

Founded in New Haven, Connecticut, Precipio, Inc. is a healthcare solutions company dedicated to providing diagnostic products, reagents, and services primarily in the United States. The company specializes in diagnostic blood cancer testing services, catering to the growing demand for accurate and timely cancer diagnostics. Precipio's product portfolio includes IV-Cell, a proprietary cell culture media that allows for the simultaneous culturing of four hematopoietic cell lineages, and HemeScreen, a suite of robust genetic diagnostic panels tailored for hematological malignancies. Additionally, the company offers ICE-COLD PCR, a patented specimen technology that significantly enhances the sensitivity of molecular tests, making it a vital tool for detecting low-abundance mutations in blood samples. The company also provides COVID-19 antibody tests, showcasing its adaptability to emerging health challenges. Precipio has established collaborations with various academic institutions that specialize in cancer research, diagnostics, and treatment, further solidifying its position in the healthcare landscape. With a dedicated workforce of 54 employees, Precipio is committed to advancing diagnostic solutions that improve patient outcomes and support healthcare professionals in their diagnostic endeavors.

What Products and Services Does PRPO Offer?

• Provide diagnostic blood cancer testing services to healthcare providers.
• Offer proprietary diagnostic products, including IV-Cell and HemeScreen.
• Develop and sell ICE-COLD PCR technology kits to bio-pharma customers.
• Conduct research collaborations with academic institutions focused on cancer diagnostics.
• Adapt to emerging health challenges by providing COVID-19 antibody tests.

How Does PRPO Make Money?

• Generate revenue through the sale of diagnostic products and services.
• Collaborate with academic institutions for research funding and product development.
• Provide specialized diagnostic testing services to healthcare providers and institutions.
• Sell proprietary technologies to bio-pharma companies for research and development.

What Industry Does PRPO Operate In?

The medical diagnostics industry is experiencing significant growth, driven by an increasing prevalence of chronic diseases and advancements in technology. The global market for diagnostic testing is projected to reach $78 billion by 2025, with a CAGR of 6.5%. Precipio, Inc. operates within this expanding market, focusing on blood cancer diagnostics, which is a critical area given the rising incidence of hematological malignancies. The competitive landscape includes established players and emerging companies, with a growing emphasis on precision medicine and personalized diagnostics. Precipio's proprietary technologies, such as ICE-COLD PCR, provide a competitive edge in enhancing test sensitivity, positioning the company well within this dynamic industry.

Who Are PRPO's Key Customers?

• Healthcare providers seeking accurate diagnostic testing solutions.
• Bio-pharma companies requiring advanced diagnostic technologies for research.
• Academic institutions focused on cancer research and diagnostics.
• Patients undergoing testing for blood cancers and related conditions.

How Precipio, Inc. Is Valued

Precipio, Inc. carries a market capitalization of $41.8M, placing it in the micro-cap category. Relative to its peer group, PRPO's quantitative score of 26/100 is below the peer average of 57/100.

Company Profile

Precipio, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Ilan Danieli. PRPO has traded publicly since 2017.

ROE -7%Key Financial Metrics

Return on equity for Precipio, Inc. stands at -6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Precipio, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.80 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Precipio, Inc. revenue of about $80.3M for fiscal 2026, with EPS near $27.40.

Net sellingInsider Activity

Over the past six months, Precipio, Inc. insiders filed 8 SEC Form 4 transactions — 4 sales and 4 purchases. On net that is roughly 3K shares disposed (about $73K), a signal worth weighing alongside the fundamentals.

PRPO Financials

PRPO Latest News

PRPO Analyst Consensus

PRPO MoonshotScore

Precipio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources